Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Airflow Limitation”

28 trials

Showing 20 of 28 results

Large-scale testing (Phase 3)Study completedNCT02487498
What this trial is testing

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Who this might be right for
Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals 355
Large-scale testing (Phase 3)Study completedNCT01697696
What this trial is testing

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

Who this might be right for
Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals 511
Post-approval studies (Phase 4)UnknownNCT04509661
What this trial is testing

Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation

Who this might be right for
Bronchiectasis Adult
Shanghai Pulmonary Hospital, Shanghai, China 200
Not applicableLooking for participantsNCT06612294
What this trial is testing

Asthma Symptom Perception Study

Who this might be right for
Asthma
Icahn School of Medicine at Mount Sinai 300
Large-scale testing (Phase 3)Study completedNCT01682863
What this trial is testing

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Who this might be right for
Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals 614
Not applicableStudy completedNCT01485159
What this trial is testing

Airflow Limitation in Cardiac Diseases in Europe

Who this might be right for
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline 3,000
Post-approval studies (Phase 4)Study completedNCT01010178
What this trial is testing

Can Airflow Limitation in Chronic Obstructive Pulmonary Disease (COPD) be Reversible by Drugs?

Who this might be right for
Chronic Obstructive Pulmonary Disease
Baqiyatallah Medical Sciences University 64
Not applicableLooking for participantsNCT00576069
What this trial is testing

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Who this might be right for
Asthma
Gelb, Arthur F., M.D. 60
Not applicableUnknownNCT00865293
What this trial is testing

Expiratory Airflow Limitation in Subjects With Obesity

Who this might be right for
Obesity
Medical Center Alkmaar 30
Post-approval studies (Phase 4)Looking for participantsNCT01225913
What this trial is testing

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Who this might be right for
Asthma
Gelb, Arthur F., M.D. 50
Large-scale testing (Phase 3)Study completedNCT01610037
What this trial is testing

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Who this might be right for
Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals 1,215
Not applicableStudy completedNCT07788092
What this trial is testing

Dupilumab in Type 2-Inflamed COPD Across the Full Spectrum of Airflow Limitation: An Italian Multicentre Retrospective Cohort Study

Who this might be right for
COPD (Chronic Obstructive Pulmonary Disease)COPDEosinophilia
Azienda Ospedaliera di Perugia 40
Large-scale testing (Phase 3)Study completedNCT02487446
What this trial is testing

Efficacy and Safety Study of QVA149 in COPD Patients

Who this might be right for
Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals 357
Large-scale testing (Phase 3)WithdrawnNCT01757015
What this trial is testing

Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS

Who this might be right for
Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals
Post-approval studies (Phase 4)Study completedNCT02125734
What this trial is testing

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients

Who this might be right for
Chronic Obstructive Pulmonary DiseaseCOPD
Novartis Pharmaceuticals 88
Not applicableUnknownNCT00799305
What this trial is testing

Correlation of Airflow Limitation and Other Respiratory Characteristics With Radiologic Changes of Lung Structure

Who this might be right for
Chronic Obstructive Pulmonary Disease
Hillel Yaffe Medical Center 30
Not applicableStudy completedNCT02600221
What this trial is testing

A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China

Who this might be right for
Asthma-COPD Overlap Syndrome
AstraZeneca 2,016
Large-scale testing (Phase 3)Study completedNCT01727141
What this trial is testing

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Who this might be right for
Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals 1,042
Testing effectiveness (Phase 2)Study completedNCT02130193
What this trial is testing

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

Who this might be right for
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline 102
Large-scale testing (Phase 3)Study completedNCT01712516
What this trial is testing

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Who this might be right for
Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals 1,001
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation